Perioperative SOX plus sintilimab vs P-SOX and CAPOX in advanced gastric cancer: A real-world comparison

Table 1 Basic patient characteristics and short-term efficacy, n (%)

Variables1	Total (n = 323)	P-SOX (n = 148)	SOX + XDL (n = 101)	CAPOX (n = 74)	Statistic	P value
Age					χ² = 1.19	0.551
≤ 60	175 (54.18)	83 (56.08)	56 (55.45)	36 (48.65)
> 60	148 (45.82)	65 (43.92)	45 (44.55)	38 (51.35)
Sex					χ² = 2.67	0.263
Male	250 (77.40)	120 (81.08)	73 (72.28)	57 (77.03)
Female	73 (22.60)	28 (18.92)	28 (27.72)	17 (22.97)
ASA					χ² = 0.90	0.638
1 + 2	281 (87.00)	126 (85.14)	90 (89.11)	65 (87.84)
3	42 (13.00)	22 (14.86)	11 (10.89)	9 (12.16)
Differentiation					χ² = 0.69	0.953
Well	90 (27.86)	41 (27.70)	29 (28.71)	20 (27.03)
Moderate	94 (29.10)	43 (29.05)	27 (26.73)	24 (32.43)
Poorly	139 (43.03)	64 (43.24)	45 (44.55)	30 (40.54)
cT stage					χ² = 4.92	0.296
2	76 (23.53)	29 (19.59)	26 (25.74)	21 (28.38)
3	167 (51.70)	75 (50.68)	55 (54.46)	37 (50.00)
4	80 (24.77)	44 (29.73)	20 (19.80)	16 (21.62)
cN stage					χ² = 1.70	0.428
Negative	93 (28.79)	44 (29.73)	32 (31.68)	17 (22.97)
Positive	230 (71.21)	104 (70.27)	69 (68.32)	57 (77.03)
cTNM					χ² = 12.55	0.051
II	161 (49.85)	65 (43.92)	59 (58.42)	37 (50.00)
IIIA	32 (9.91)	19 (12.84)	7 (6.93)	6 (8.11)
IIIB	68 (21.05)	29 (19.59)	25 (24.75)	14 (18.92)
IIIC	62 (19.20)	35 (23.65)	10 (9.90)	17 (22.97)
RECIST1.1					χ² = 3.26	0.196
Ineffective	124 (38.39)	59 (39.86)	32 (31.68)	33 (44.59)
Effective	199 (61.61)	89 (60.14)	69 (68.32)	41 (55.41)
Lauren					χ² = 2.18	0.704
Diffuse	117 (36.22)	54 (36.49)	35 (34.65)	28 (37.84)
Mixed	150 (46.44)	64 (43.24)	51 (50.50)	35 (47.30)
Intestinal	56 (17.34)	30 (20.27)	15 (14.85)	11 (14.86)
Location					χ² = 2.03	0.730
Upper	80 (24.77)	32 (21.62)	27 (26.73)	21 (28.38)
Middle	129 (39.94)	59 (39.86)	40 (39.60)	30 (40.54)
Lower	114 (35.29)	57 (38.51)	34 (33.66)	23 (31.08)
TRG					χ² = 14.59	< 0.001
Ineffective	86 (26.63)	41 (27.70)	15 (14.85)	30 (40.54)
Effective	237 (73.37)	107 (72.30)	86 (85.15)	44 (59.46)
Tumor diameter					χ² = 2.27	0.686
≤ 2	126 (39.01)	55 (37.16)	39 (38.61)	32 (43.24)
2-5	133 (41.18)	59 (39.86)	45 (44.55)	29 (39.19)
≥ 5	64 (19.81)	34 (22.97)	17 (16.83)	13 (17.57)

¹Tumor location is classified as upper 1/3, middle 1/3, lower 1/3, diffuse tumor-node-metastasis staging according to the American Joint Committee on Cancer.

ASA: American Society of Anesthesiologists Score; RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor regression grade; cTNM: Clinical tumor-node-metastasis; P-SOX: Nab-paclitaxel plus oxaliplatin and S-1; SOX + XDL: Oxaliplatin plus S-1 combined with sintilimab; CAPOX: Capecitabine plus oxaliplatin.